Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Myelodysplastic Syndrome: early-phase trial registry
12 of 20 indexed Recurrent Myelodysplastic Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 12 currently recruiting · #848 of 28,707 conditions by registered trial count
Recurrent Myelodysplastic Syndrome: 20 US clinical trials tracked, 12 recruiting.
Recurrent Myelodysplastic Syndrome is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition recurrent-myelodysplastic-syndrome
OPEN 12 | RECR 60% | LATE 0 | EARLY 20 | RANK #848 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Recurrent Myelodysplastic Syndrome lists 12 open slots (60% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Myelodysplastic Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Myelodysplastic Syndrome is recruiting above its size-band peers.
12 of 20 indexed trials (60%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Myelodysplastic Syndrome research.
M.D. Anderson Cancer Center accounts for 8 of 20 trials (40%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Myelodysplastic Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 20 trials that report a genuine target (sentinel values excluded). 18 of those (90%) plan for fewer than 100 participants.
-
Recurrent Myelodysplastic Syndrome research is mostly interventional.
20 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
NCT04375631
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02392572
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT04239157
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03661307
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
NCT04493138
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
NCT03969446
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT06484062
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04128748
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT04734990
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
NCT03816319
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT06928662
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03326921
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02530463
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT02890329
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT04550442
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
National Cancer Institute (NCI)
NCT03953898
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
National Cancer Institute (NCI)
NCT05146739
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
NCT05564650
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
NCT04250051
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT01822509
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Myelodysplastic Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Myelodysplastic Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Myelodysplastic Syndrome page
20 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Recurrent Myelodysplastic Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Recurrent Myelodysplastic Syndrome trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Myelodysplastic Syndrome condition card totals 20 registered trials; most-linked intervention Decitabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.